Neuropeptides

Study Ties CGRP–RAMP1 Signaling to GI Tumor Growth, Pointing to Repurposed Migraine Therapies

Researchers report a nerve–tumor pathway in colorectal and stomach cancers that has prompted plans to test approved CGRP inhibitors.